Company intelligence / Profile preview

Auragent Bioscience

St. Louis, Missouri, USAlegacy.www.sbir.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Auragent Bioscience has developed an ultrasensitive multiplex immunoassay platform capable of detecting protein biomarkers at extremely low concentrations in biological fluids such as blood, serum, and urine. The company’s technology aims to improve sensitivity and throughput for bioanalytical applications in research and diagnostics. No clinical trial results are reported as the company focuses on enabling technologies rather than direct therapeutic candidates.[1][7]

Therapeutic areas: Other
Modalities: ImmunoassaysBioanalytical techniques for protein biomarkers[1][7]
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Auragent Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auragent Bioscience.

Explore the full profile